Latest big hope against Alzheimer's falls flat in clinical trials

Share this article:
A promising potential treatment for Alzheimer's disease has failed to produce results in the late stages of a clinical trial, according to recent reports.

The drug, Dimebon, had shown immense promise for halting cognitive decline during early testing, according to a report in the New York Times. Originally marketed as an antihistamine in Russia during the 1980s, Dimebon was being developed as an Alzheimer's treatment by San Francisco-based Medivation and global drug giant Pfizer. The results of the first late-stage clinical trial, however, showed that the once-promising drug had virtually no effect after six months of treating mild to moderate Alzheimer's compared with a placebo, the Times reported.

Tests will continue to determine whether Dimebon is effective when coupled with other medications, and the drug is still being tested as a potential treatment for Huntington's disease, the newspaper said. The price of Medivation stock fell by nearly two-thirds to $13.10 Wednesday.


Share this article:

More in News

Bill addressing admission status receives praise

A bill that would require hospitals to give patients a formal notice of their admission status has received strong support from healthcare associations.

Increased 'bed taxes' on nursing facilities warrant stricter federal oversight, report states

States have been increasingly taxing skilled nursing facilities and other healthcare providers to fund Medicaid in recent years, and federal authorities should look more closely at this trend, according to a government report released Tuesday.

Last chance: Tech Awards deadline arrives

Last chance: Tech Awards deadline arrives

There are hours left for innovative long-term care providers to enter the third annual McKnight's Excellence in Technology Awards. Submissions will be accepted until the stroke of midnight tonight.